Akari Therapeutics PLC宣布,其提交的研究摘要已获得第40届癌症免疫治疗学会(SITC)年会口头报告的资格。
Akari Therapeutics PLC宣布,其提交的研究摘要已获得第40届癌症免疫治疗学会(SITC)年会口头报告的资格。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.